((3-bromo-4-fluorobenzyl)oxy)(tert-butyl)dimethylsilane | 655237-57-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ((3-bromo-4-fluorobenzyl)oxy)(tert-butyl)dimethylsilane
• 英文别名: (3-Bromo-4-fluorophenyl)methoxy-tert-butyl-dimethylsilane
• CAS: 655237-57-3
• 化学式: C₁₃H₂₀BrFOSi
• 分子量: 319.289
• InChiKey: HMZDCJNPEKOOKB-UHFFFAOYSA-N

物化性质

• 沸点：
  305.2±27.0 °C(Predicted)
• 密度：
  1.194±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.11
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  ((3-bromo-4-fluorobenzyl)oxy)(tert-butyl)dimethylsilane 在 正丁基锂 、 三甲基氯硅烷 、 四溴化碳 、 三异丙基硅烷 、 三氟化硼乙醚 、 三溴化硼 、 1,2-二溴乙烷 、 三苯基膦 、 锌 作用下， 以 四氢呋喃 、 正己烷 、 二氯甲烷 、 乙腈 为溶剂， 反应 20.0h， 生成 (1S)-1,5-anhydro-1-(2-fluoro-5-{[1-(methoxycarbonyl)azulen-2-yl]methyl}phenyl)-D-glucitol
  参考文献：
  名称：

  Synthesis and biological evaluation of C-glucosides with azulene rings as selective SGLT2 inhibitors for the treatment of type 2 diabetes mellitus: Discovery of YM543

  摘要：

  Here, a series of C-glucosides with azulene rings in the aglycon moiety was synthesized and the inhibitory activities toward hSGLT1 and hSGLT2 were evaluated. Starting from the azulene derivative 7 which had relatively good SGLT2 inhibitory activity, compound 8a which has a 3-[(azulen-2-yl)methyl]phenyl group was identified as a lead compound for further optimization. Introduction of a phenolic hydroxyl group onto the central benzene ring afforded a potent and selective SGLT2 inhibitor 8e, which reduced blood glucose levels in a dose-dependent manner in rodent diabetic models. A mono choline salt of 8e (YM543) was selected as a clinical candidate for use in treating type 2 diabetes mellitus. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.03.067
• 作为产物：
  描述：

  3-溴-4-氟苯甲酸 在 咪唑 、 硼烷四氢呋喃络合物 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 生成 ((3-bromo-4-fluorobenzyl)oxy)(tert-butyl)dimethylsilane
  参考文献：
  名称：

  通过锂-溴化物交换合成带有醛、频哪醇硼烷或羧酸基序的苯甲醇结构单元

  摘要：

  一系列有用的二取代苯甲醇结构单元已经在溴化锂交换中以数克的量合成，以高产率得到醛、羧酸和频哪醇硼烷。

  DOI：

  10.1055/s-0033-1340069

文献信息

• 2-Heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
  申请人：Neustadt R. Bernard

  公开号：US20070066620A1

  公开（公告）日：2007-03-22

  Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein R is R 1 -isoxazolyl, R 1 -oxadiazolyl, R 1 -dihydrofuranyl, R 1 -pyrazolyl, R 1 -imidazolyl, R 1 -pyrazinyl or R 1 -pyrimidinyl; R 1 is 1, 2 or 3 substituents selected from H, alkyl, alkoxy and halo; Z is optionally substituted-aryl, or optionally substituted-heteroaryl; are disclosed, as well as their use in the treatment of central nervous system diseases, in particular Parkinson's disease and Extra Pyramidal Syndrome, pharmaceutical compositions comprising them, and combinations with other agents.

  具有结构式I或其药用可接受盐的化合物，其中R是R1-异噁唑基、R1-噁唑啉基、R1-二氢呋喃基、R1-吡唑基、R1-咪唑基、R1-吡啶基或R1-嘧啶基；R1是从H、烷基、烷氧基和卤代中选择的1、2或3个取代基；Z是可选择取代的芳基或可选择取代的杂芳基；公开了这些化合物及其在治疗中枢神经系统疾病，特别是帕金森病和额外锥体综合征中的用途，包括它们的药物组合物和与其他药剂的组合。
• 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
  申请人：Schering Corporation

  公开号：US20040220194A1

  公开（公告）日：2004-11-04

  Compounds having the structural formula I 1 or a pharmaceutically acceptable salt thereof, wherein R is 2 R 1 , R 2 , R 3 , R 4 and R 5 are H, alkyl or alkoxyalkyl; R 6 is H, alkyl, hydroxyalkyl or —CH 2 F; R 7 , R 8 and R 9 are H, alkyl, alkoxy, alkylthio, alkoxyalkyl, halo or —CF 3 ; and Z is optionally substituted aryl, heteroaryl or heteroaryl-alkyl are disclosed. Also disclosed is the use of compounds of formula I in the treatment of central nervous system diseases, in particular Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, and pharmaceutical compositions comprising them.

  具有结构式I或其药用可接受盐的化合物，其中R是R1，R2，R3，R4和R5为H，烷基或烷氧基烷基；R6为H，烷基，羟基烷基或—CH2F；R7，R8和R9为H，烷基，烷氧基，烷硫基，烷氧基烷基，卤素或—CF3；以及Z是可选择地取代的芳基，杂环芳基或杂环芳基烷基。还公开了化合物I的应用于治疗中枢神经系统疾病，特别是帕金森病，单独或与其他治疗帕金森病的药剂联合使用，以及包含它们的药物组合物。
• Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
  申请人：Neustadt R. Bernard

  公开号：US20050239795A1

  公开（公告）日：2005-10-27

  Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, furanyl, thienyl, pyridyl, pyridyl N-oxide, oxazolyl or pyrrolyl, or cycloalkenyl R 1 , R 2 , R 3 , R 4 and R 5 are H, alkyl or alkoxyalkyl; and Z is optionally substituted aryl or heteroaryl are disclosed. Also disclosed is the use of compounds of formula I in the treatment of central nervous system diseases, in particular Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, and pharmaceutical compositions comprising them.

  具有结构式I或其药学上可接受的盐的化合物，其中R是可选择地取代的苯基、呋喃基、噻吩基、吡啶基、吡啶N-氧化物基、噁唑基或吡咯基，或环烯基R1、R2、R3、R4和R5为H、烷基或烷氧基烷基；Z是可选择地取代的芳基或杂芳基。还公开了公式I化合物在治疗中枢神经系统疾病，特别是帕金森病中的用途，单独或与其他治疗帕金森病的药剂联合使用，以及包含它们的药物组合物。
• Synthesis of Benzyl Alcohol Building Blocks Bearing an Aldehyde, Pinacol Borane or Carboxylic Acid Motif via Lithium–Bromide Exchange
  作者：Kevin Blades、Matthew Box、Nick Howe、Paul Kemmitt、Gillian Lamont

  DOI：10.1055/s-0033-1340069

  日期：——

  A range of useful disubstituted benzyl alcohol building blocks have been synthesised in multigram quantities in a lithium–bromide exchange to give aldehyde, carboxylic acid and pinacol ­boranes in high yields.

  一系列有用的二取代苯甲醇结构单元已经在溴化锂交换中以数克的量合成，以高产率得到醛、羧酸和频哪醇硼烷。
• Synthesis and biological evaluation of C-glucosides with azulene rings as selective SGLT2 inhibitors for the treatment of type 2 diabetes mellitus: Discovery of YM543
  作者：Kazuhiro Ikegai、Masakazu Imamura、Takayuki Suzuki、Keita Nakanishi、Takeshi Murakami、Eiji Kurosaki、Atsushi Noda、Yoshinori Kobayashi、Masayuki Yokota、Tomokazu Koide、Kazuhiro Kosakai、Yasufumi Ohkura、Makoto Takeuchi、Hiroshi Tomiyama、Mitsuaki Ohta

  DOI：10.1016/j.bmc.2013.03.067

  日期：2013.7

  Here, a series of C-glucosides with azulene rings in the aglycon moiety was synthesized and the inhibitory activities toward hSGLT1 and hSGLT2 were evaluated. Starting from the azulene derivative 7 which had relatively good SGLT2 inhibitory activity, compound 8a which has a 3-[(azulen-2-yl)methyl]phenyl group was identified as a lead compound for further optimization. Introduction of a phenolic hydroxyl group onto the central benzene ring afforded a potent and selective SGLT2 inhibitor 8e, which reduced blood glucose levels in a dose-dependent manner in rodent diabetic models. A mono choline salt of 8e (YM543) was selected as a clinical candidate for use in treating type 2 diabetes mellitus. (C) 2013 Elsevier Ltd. All rights reserved.